Cidofovir is a potent, broad spectrum antiviral agent with activity in vitro and in vivo against cytomegalovirus and other members of the herpesvirus family, as well as certain other DNA viruses. After uptake into cells it is converted enzymatically to cidofovir diphosphate, a structural analogue of deoxycytidine triphosphate, which selectively inhibits viral DNA polymerases relative to host cell polymerases. Cross-resistance to cidofovir is not usually seen with human cytomegalovirus isolates that are foscarnet-resistant, or isolates that are ganciclovir-resistant due to a deficiency in ganciclovir phosphorylation. Cross-resistance is seen, however, with isolates that are ganciclovir resistant due to polymerase mutations. A prolonged elimination phase seen in vivo, correlates with a long intracellular half-life seen in vitro and allows for efficacy in-animal models of virus infection with infrequent dosing or prophylaxis. Clinical studies of intravenous cidofovir in cytomegalovirus retinitis in patients with AIDS are claimed to show delay of retinitis progression with maintenance doses given once every 2 weeks.
Introduction
Cidofovir is the generic name for 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine, which has also been referred to as HPMPC and GS-504. Cidofovir is a member of a new class of antiviral agents (phosphonylmethylether nucleotide analogues) first described by De Clercq and Holy (De Clercq et al., 1986) . Cidofovir shows potent in-vitro activity against a broad spectrum of herpesviruses, including human cytomegalovirus (HCMV), adenovirus and papilloma virus. Human clinical studies with cidofovir are ongoing against diseases caused by HCMV, herpes simplex virus (HSV) and human papilloma virus (HPV). The first approved indication is expected to be the treatment of HCMV retinitis in patients with AIDS.
Potent activity in animal models of viral disease has been demonstrated (e.g. HSV-1 and 2 infections in mice and guinea pigs, murine CMV in mice, rat CMV in rats and simian varicella virus in monkeys). In addition to activity in animal models utilizing standard protocols for drug administration, cidofovir is also efficacious with infrequent dosing (less than daily) or when given as a single prophylactic dose up to a week prior to infection.
Thus, cidofovir represents a significant, potential treatment for a broad spectrum of viral diseases. This review provides a detailed summary of the antiviral properties and mechanism of action of cidofovir. Since ganciclovir and foscarnet are the first two approved therapies for HCMV retinitis, comparisons between data for cidofovir and these other drugs are presented where available. Structures of the three drugs are compared in Fig. 1 . Although the anti-CMV activity is the major focus, other experiments are described where the data have contributed to an understanding of the broad-spectrum antiviral activity and the pharmacology of cidofovir.
Antimicrobial activity
The antiviral spectrum of cidofovir includes members of the herpesvirus family (CMV, HSV-1, HSV-2, VZV) as detailed below. In addition, activity has been shown for EBV (Lin et al., 1991) , human herpesvirus type 6 (Reyman et al., 1995) , adenovirus (AV) (Gordon et al., 1992 (Gordon et al., ,1994 , vaccinia virus (VV), polyoma virus (Snoeck, R. et al. Abstract, 35th Interscience Conference on Antimicrobial Agents & Chemotherapy, San Francisco, 17-20 September, 1995) , papilloma virus (Kurtzman, G. et al. Abstract, 33rd Interscience Conference on Antimicrobial Agents & Chemotherapy, New Orleans, 17-20 October, 1993) and hepatitis B virus (Heijtink et al., 1994) . Only the (S)-enantiomer of cidofovir is biologically active as an antiviral agent.
De Clercq et al. (1987) originally reported on the antiviral activity of cidofovir. Activity was observed against ?!~O HO-P-C I ' HO OH Foscarnet HCMV, HSV-1, HSV-2, thymidine kinase deficient HSV-1 (TK-HSV-1), VV and AV at concentrations well below those required to inhibit the growth of host cells (Table 1) .
Other examples of the wide spectrum of activity, as well as of increased sensitivity of acyclovir-resistant (ACV R ) ·HSV isolates to cidofovir, have been described (Bronson et et., 1989; Holy et a/., 1990; Martin and Hitchcock, 1991) . A recent study has shown that the increased sensitivity to cidofovir of ACV R HSV is explained by the inability of these mutant strains to induce intracellular dCTP increases during infection. Cidofovir diphosphate, which inhibits viral polymerase in competition with dCTP, is thus a more effective inhibitor of viral replication (Mendel et a/., 1995a) . A compilation of reported anti-HCMV activities of cidofovir, ganciclovir and foscarnet is presented in Table  2 . Several different assays were used to study the anti-HCMV activities of these three compounds, including plaque reduction assays, cytopathic effect assays, flow cytometry assays, DNA hybridization assays, fluorometrical assays and in situ ELISA assays. Compared to ganciclovir and foscarnet, cidofovir is the most potent compound against HCMV replication, regardless of the assay used. Cidofovir is also the most potent of the three compounds against replication of either wild-type or drugresistant HCMV strains.
Similar results for the relative anti-HCMV activities of cidofovir, ganciclovir and foscarnet against 17 clinical isolates were shown by Andrei et el., 1991 . Shigeta et at. (1991 also reported potent activity for cidofovir, with an average EC 5 0 of 0.8 J.lM for 12 clinical isolates of HCMV from bone marrow transplant patients. Table 3 shows the prolonged anti-HCMV activity of cidofovir (Neyts et a/., 1991a) . Cidofovir maintains its anti-HCMV activity when the cell culture is treated for a 24 h period, 2 days prior to infection by HCMV. Ganciclovir does not show any anti-HCMV activity under these conditions. Relative to continuous presence of the drug during post-infection incubation, ganciclovir loses 98% of its anti-HCMV activity when the cell culture is treated for 24 hand then the drug removed prior to infection by HCMV. Cidofovir also causes a reduction in viral yield when the cell culture is treated for various periods of time after HCMV infection (Neyts et et., 1990) . Similar data using HSV have also been reported (Ho eta/., 1992) .
Mechanism of action
Cidofovir was shown to inhibit HCMV DNA synthesis in cell culture in a concentration-dependent manner within the concentration range of 0.04-4 J.lg mr" (Neyts et a/., IC so([1M) Snoeck at al., 1988 , 1991 , Bronson at al., 1989 , Holy at al., 1990 , Kern 1991 , Andrei at al., 1991 , Neyts at al., 1991b , Sullivan and Coen, 1991 , Slanat at al., 1991 , Tatarowicz at aI., 1992 , Otova at al., 1992 , Lurain at aI., 1992 , Shigeta at al., 1991 C Data are the mean of 9 mid or late therapy isolates reported in Stanat at al., 1991. d Data are the mean of 14 results reported in Kern, 1991 , Tatarowicz at al., 1992 Data are the mean of 2 results reported in Sullivan and Coen, 1991 . 
1990
). At 4/.1.g mr', viral DNA synthesis was completely blocked. Cidofovir was more inhibitory to HCMV replication and HCMV DNA synthesis than ganciclovir (Neyts et et., 1990) . Both compounds affect cell proliferation and cellular DNA synthesis only at a concentration that is 100to 500-fold higher than effective antiviral concentrations. A limited time of exposure to cidofovir (as short as 6 h post-infection) of the HCMV-infected cells was adequate to afford a pronounced and prolonged inhibition of viral DNA synthesis and virus replication. Ganciclovir only affords a weak and transient inhibition of HCMV DNA synthesis and virus replication following exposure to cells for a short time.
Cidofovir is a nucleotide analogue of deoxycytidine monophosphate (dCMP). Analogous to the metabolism of dCMP to dCTP, cidofovir in cells is converted to cidofovir Xiong at al., 1995 . b Ho at al., 1992 . C Cherrington at al., 1994 HCMV DNA polymerase" HSV-1 DNA polymerase" HSV-2 DNA polymerase" DNA polymerase a b DNA polymerase pc DNA polymerase f Enzyme Table 4 . The inhibition constants of cidofovir diphosphate against DNA polymerases from HCMV, HSV and human cells diphosphate, a triphosphate analogue. Cidofovir diphosphate is the active lritracellular metabolite, and the inhibition constants of cidofovir diphosphate with respect to DNA polymerases from human cells, HCMV, HSV-1, and HSV-2 have been reported (Table 4 ). The Kj data indicate that cidofovir diphosphate is a poor inhibitor of human DNA polymerases ex,~, and y and that concentrations that inhibit viral polymerases are considerably lower (8-to 600-fold) than those that affect human enzymes. Selectivity is thus achieved due to the higher affinity for viral DNA polymerases (including HCMV DNA polymerase) than for human DNA polymerases.
Cidofovir diphosphate acts as both an inhibitor and an alternative substrate for HCMV DNA polymerase and reduces the rate of DNA synthesis (Xiong et al., 1995) . This apparent inhibition is the result of cidofovir diphosphate acting as an alternative substrate in competition with dCTP. The kinetics of incorporation of cidofovir, or extension of cidofovir after incorporation. have been measured using HCMV DNA polymerase with various synthetic primer/template hybrids. A primer/template hybrid, in which the next unpaired residue on the template was G, Treatment period before infection was used to assess the kinetics of incorporation of cidofovir diphosphate relative to dCTP. The Km for cidofovir diphosphate was 18.7 11M and the Km for dCTP was 0.67 11M, suggesting less efficient binding to the active site for cidofovir diphosphate. Vmax for cidofovir diphosphate was also lower than for dCTP resulting in an overall efficiency (V m ax Km-1 ) of 0.02 for use of cidofovir diphosphate by the enzyme. Another primer/template hybrid was prepared in which the 3 '-terminus of the primer was cidofovir, and the next unpaired residue on the template was G. The kinetics of dCTP incorporation were considerably changed (Km increased 5.7-fold and V m ax decreased 2.1-fold) compared with use of a primer with a natural nucleotide at the 3'-terminus; the overall efficiency of incorporation dropping more than 10-fold.
Primer extension experiments were used to assess other properties of cidofovir incorporation by HCMV DNA polymerase (Xiong et a/., 1995) . For example, the 3' to 5' exonuclease activity of the polymerase does not excise cidofovir. Incorporation of two cidofovir residues, either consecutively or separated by a single natural nucleotide, results in termination of further DNA synthesis; this may be the major mechanism by which cidofovir exerts its anti-HCMV effect. The inhibition of DNA synthesis by cidofovir diphosphate and the inability of HCMV DNA polymerase to excise incorporated cidofovir from DNA provide a mechanistic rationale for the anti-HCMV activity of cidofovir and, in part, for its prolonged antiviral action.
The uptake of cidofovir into cells is slow, but once inside cells, cidofovir and its metabolites persist for a long period of time, thus allowing for infrequent dosing. Cellular uptake of cidofovir has been characterized in Vero cells using tritium-labelled cidofovir (Connelly et a/., 1993) .
Uptake was temperature-sensitive, inhibited by colchicine and stimulated by phorbol myristate acetate, suggesting a fluid-phase endocytosis mechanism. Uptake by this mechanism is much slower than the uptake of nucleoside analogues that utilize nucleoside transporters or pass through the cell membranes by diffusion.
Once in cells, cidofovir is metabolized to the cidofovir monophosphate, cidofovir diphosphate and cidofovir phosphate-choline (Fig. 2) . This pathway was shown to be operative for MRC-5 cells (Ho et el., 1992) , human embryonic lung cells (Cihlar et a/., 1992) and Vero cells (Aduma et el., 1995) . The enzymes involved include pyrimidine nucleoside monophosphate kinase which phosphorylates cidofovir to cidofovir monophosphate, and CTP:phosphorylcholine cytidylyltransferase, which catalyses the formation of cidofovir phosphate-choline from oldofovir diphosphate and choline phosphate (Cihlar et et., 1992) . Upon removal of cidofovir from the medium of MRC-5 cells, the concentrations of the metabolites in cells decrease slowly, with half-lives of ",6, 17, and > 48 h measured for cidofovir monophosphate, cidofovir diphos-phate, and cidofovir phosphate-choline, respectively (Ho et et., 1992) . The long half-lives for cidofovir monophosphate and cidofovir diphosphate (t 1 / 2 = 24 and 65 h, biphasic) and cidofovir phosphate-choline (t 1 / 2 = 87 h) have also been measured in Vero cells (Aduma et a/., 1995) .
The biphasic decline for cidofovir diphosphate suggests that its inherent degradation half life (24 h) is ultimately superseded by its rate of formation from degradation of the longer lived choline-adduct. Thus, the long half-lives of cidofovir diphosphate and cidofovir phosphate-choline, and the potential for cidofovir phosphate-choline to act as a reservolrfor the generation of cidofovir diphosphate, are consistent with the prolonged antiviral activity of cidofovir.
In common with cidofovir, the general mechanism of action of ganciclovir involves formation of a triphosphate which is an inhibitor of HCMV DNA polymerase and an alternate substrate for HCMV DNA polymerase (Reid et a/., 1988) . However, the antiviral effect of ganciclovir against HCMV depends, to a large extent, on increased phosphorylation of ganciclovir in HCMV-infected cells (Biron et a/., 1985) . This phosphorylation is catalysed by the product of the virus-encoded UL97 gene, a protein kinase homologue of unknown function (Sullivan et a/., 1992; Littler et a/., 1992) . Thus, whereas cidofovir is not dependent on viral infection for its phosphorylation and can therefore prime cells to an antiviral state prior to infection by herpesviruses, the antiviral metabolite from ganciclovir cannot be formed to any appreciable extent in cells unless they are already infected and expressing viral enzymes. The independence of cidofovir activation from viral enzyme expression also precludes one option by which the virus can become resistant to drugs like ganciciovir. Another implication of the difference in mechanism is that ganciclovir must be given frequently so that newly infected cells can produce the active form of the drug.
Resistance
For drug resistant HCMV selected in vitro, cross-resistance to cidofovir is seen with ganciclovir-selected mutations in DNA polymerase, but not with mutations in UL97. Cidofovir-selected mutants are cross-resistant to ganciclovir, but susceptible to foscarnet. Cross-resistance between foscarnet and cidofovir is not seen with foscarnet-selected mutants.
In-vitro selections with ganciclovir have led to the identification of a point mutation in the UL97 (G1380T) open reading frame that results in an M4601 amino acid substitution in three independently isolated ganciclovir-resistant HCMV strains derived from AD169. This point mutation was transferred into AD169 to produce the recombinant strain, R6HS. R6HS was found to be 10-fold less sensitive to ganciclovir than AD169, but susceptibility to cidofovir was unchanged (Lurain et a/., 1994) .
I HO HO OH

Cidofovir monophosphate
Cidovir, potent anti-herpes activity 119 . Other in-vitro selections with ganciclovir have led to identification of point mutations in the HCMV DNA polymerase gene (L5011; mutation of leucine to isoleucine at amino acid residue 501, or F412 V; mutation of phenylalanine to valine at amino acid residue 412). These mutations confer 5-and 8-fold decreases in susceptibility to ganciclovir and cidofovir, respectively . In another ganciclovir selected mutant, a A987G (mutation of alanine to glycine at amino acid residue 987) mutation within the conserved region V of the HCMV DNA polymerase (Sullivan et el., 1993) confers a 4-fold decrease in susceptibility to ganciclovir and an 11-fold decrease in susceptibility to cidofovir. Also, two resistant mutants selected with ganciclovir that were resistant to ganciclovir and cidofovir but not foscarnet were both shown to contain two mutations (K513N and V812L) in the polymerase gene (Cherrington, J. M. et at. Abstract, 35th Interscience Conference on Antimicrobial Agents & Chemotherapy, San Francisco, 17-20 September, 1995) . In addition, Snoeck et at. (1995a) have also shown ganciclovir-selected resistant mutants are cross-resistant to cidofovir but retain susceptibility to foscarnet.
Foscarnet-resistant HCMV isolates selected with toscarnet in vitro have been described by two independent laboratories (Sullivan and Coen, 1991; Snoeck et sl., 1995a) . These isolates remain sensitive to inhibition by cidofovir and ganciclovir.
In-vitro selections with cidofovir, using laboratory strain AD169, resulted in two clones with increased IC so values for both cidofovir and ganciclovir (Snoeck et a/., 1995a) . Susceptibility to foscarnet was unchanged in these clones. Similar results generated independently showed that a strain selected with cidofovir had 20-, 12-and 1.2-fold decreases in susceptibility to cidofovir, ganciclovir and foscarnet, respectIvely (Cherrington, J. M. et at. Abstract, 35th Interscience Conference on Antimicrobial Agents & Chemotherapy, San Francisco, 17-20 September, 1995) . Sequencing of the DNA polymerase gene for this plaque purified strain, and two other independently isolated cidofovir resistant clones has revealed K513N mutations (lysine substituted to asparagine) which appear to be responsible for the resistant phenotype.
Drug resistant HCMV from clinical studies show various cross-resistance patterns. Most ganciclovir-resistant viruses are UL97 mutants and are susceptible to cidofovir and foscarnet. In the study reported by Stanat et at. (1991) , nine isolates from patients who had failed longterm ganciclovir therapy were all considered resistant with ED so values higher than those for a wild-type laboratory strain or early therapy isolates ( Table 2) . All nine isolates, and a resistant strain selected in vitro were shown to be impaired (compared to wild-type strains) in the ability to induce ganciclovir nucleotide production in cells infected with these viruses. Mutations in the UL97 gene at codons 460, 594 or 595 were subsequently confirmed in all these resistant isolates (Chou et et., 1995) . The ED so values for cidofovir for late isolates were similar to those for early isolates, suggesting that resistance to ganciclovir was not due to polymerase mutations.
A ganciclovir resistant strain (D16), that was also cross resistant to foscarnet and cidofovir (Lurain et el., 1994) , was shown to contain a mutation D301N (aspartate --7 asparagine) in the viral DNA gene polymerase. Also, in this report, another strain (D19) containing a point mutation in the polymerase gene (T5031, threonine --7 isoleucine) had high ED so values for ganciclovir (50 J..LM) and cidofovir (8 J..LM) but a wild-type value for foscarnet (150 J..LM) relative to the control strain.
In contrast to the in vitro findings, higher level resistant mutants have been isolated from a few patients treated long-term with ganciclovir or foscarnet (or in some cases, with both) that have resistance to all three agents (ganciclovir, foscarnet and cidofovir). These multiple resistant strains have numerous codon differences from wild-type laboratory strains and may be the result of several sequential mutations. For example, an isolate (RDP-1 strain, Cherrington et al., 1995) from the retina of an AIDS patient with CMV retinitis exhibited resistance to ganciclovir, foscarnet and cidofovir, with IC so values of 200 J..LM, 600 J..LM and 15 J..LM, respectively. This patient had received both ganciclovir and foscarnet therapy (but no cidofovir) prior to virus isolation. Six amino acid mutations and one amino acid insertion have been identified in the. polymerase gene. Another HCMV isolate, (C9209 strain; Erice et al., 1989; Chou et al., 1995) from a patient with CMV retinitis treated with ganciclovir alone also displayed resistance to ganciclovir, foscarnet and cidofovir, with IC so values of 100 J..LM, > 400 J..LM and 8 J..LM, respectively. This isolate has a UL97 mutation (Chou et al., 1995) and several polymerase gene substitutions.
In-vivo animal protection studies
CMVmodels
Human CMV does not infect other species. Therefore, animal models necessarily use a CMV species specific to the animal of choice, e.g. murine CMV in mice and rat CMV in rats. Animal models that have been used to test the in-vivo anti-CMV efficacy of cidofovir include murine CMV (MCMV) in immunocompetent and immunocompromised mice, rat CMV (RCMV) in immunocompromised rats with or without allogeneic bone marrow transplantation, and guinea pig CMV in guinea pigs. Cidofovir was more efficacious than ganciclovir when compared at similar doses in the murine and rat CMV models, but showed only a narrow therapeutic index in guinea pigs (Li et al., 1990) .
Cidofovir is much more effective than ganciclovir in protecting mice infected with MCMV (Kern, 1991) . Although ganciclovir provided protection from mortality in some animals, cidofovir protected a greater number and usually at a lower dose. Even when the infection was allowed to become well-established prior to initiation of treatment (e.g. 48 h), cidofovir at doses as low as 0.6 or 1.9 mg kg-1 , given twice-daily, produced >50% survival. Cidofovir maintained its efficacy even when the compound was given once every 3 days. In contrast, ganciclovir was less effective in the once every 3 days dosing regimen.
A comparison of the effects of cidofovir or ganciclovir at 10 mg kg-1 twice daily for 5 days on viral burden in MCMV-infected mice showed that cidofovir effected a greater reduction in viral titres in all organs studied than did ganciclovir (Kern, 1991) . In addition, although cidofovir was administered on days 1-5 only, virus in blood and several tissues (lung, liver, spleen, and kidney) remained undetectable from day 6 through day 21. These data illustrate the prolonged antiviral effect characteristic of cidofovir.
Cidofovir was also effective in treating MCMV-infected mice at various times after infection (Bronson et al., 1990) . Cidofovir was effective in preventing death, even when administered 48 h after infection. Infrequent dosing schedules were shown to be as efficacious as daily dosing. The efficacy of cidofovir in treating MCMV-infected mice has also been demonstrated when administered prior to infection . Treatment with a single 20 mg kg-1 dose of cidofovir at 5, 3 or 1 day prior to, or 1 day after, infection resulted in a statistically significant treatment effect on mortality compared to a placebo control group. By contrast, 20 mg kg-1 of ganciclovir had no effect under these conditions when administered as a single dose prior to or after infection.
The efficacy of cidofovir in delaying death in MCMVinfected severe combined immunodeficient mice (SCID) was compared with ganciclovir (Smee et al., 1992) . Treatment of infected mice with ganciclovir (12.5, 25, and 50 mg kg-1 of body weight for 10 days) starting 24 h after virus inoculation resulted in delays in death by 2-8 days. Cidofovir was much more potent, with doses of 1, 3.2, and 10 mg kg-1 day" (for 10 days) increasing the mean survival time by 15-30 days. Twenty-day treatments with cidofovir, starting 5 days after virus inoculation, increased the mean survival time by 24-32 days, with once-weekly (50 mg kg-1 ) treatments being equivalent in outcome to daily (10 mg kg-1 ) treatments.
In another SCID mouse model, treatment with either cidofovir or ganciclovir at various times after infection with MCMV was compared with respect to MCMV-induced disease and mortality (Neyts et al., 1992) . Under all treatment conditions, l.e, administration of the test compounds for 5 consecutive days starting on the day of infection (day 0); for 5 consecutive days starting on day 4 after the infection; 2 periods of 3 consecutive days starting on day 0 and day 9 after infection; or as a single dose on day 3 before infection, cidofovir was superior to ganciclovir in delaying the onset of the disease and in increasing the life span of the MCMV-infected mice. In a separate study, cidofovir was also efficacious in increasing the survival of SCID mice infected with MCMV (Smee et el., 1994) . Cidofovir doses of 25 mg kg-1 twice weekly or 50 mg kg-1 once weekly resulted in about a 3-fold increase in life-span compared to the placebo-treated group.
The anti-CMV activities of cidofovir and ganciclovir were compared in a RCMV in-vivo model (Stals et al., 1991) . Cidofovir was far more active than ganciclovir against RCMV infection in vivo as measured by mortality, histopathological changes and virus titres in organs of immunocompromised RCMV-infected rats. The minimal effective dosage required to prevent mortality from RCMV infection was a single dose of cidofovir at 2 mg kg-1 of body weight, compared with ganciclovir therapy twice daily at 20 mg kg-1 day' for 5 days. Furthermore, cidofovir was significantly more effective than ganciclovir in reducing virus titres in internal organs and in RCMVinduced histopathologic lesions. In contrast to ganciclovir, which does not show activity when administered 1 day before infection, cidofovir was effective even when administered as a single dose 7 days before RCMV infection.
The anti-CMV activities of cidofovir and ganciclovir were also compared in a RCMV-induced pneumonitis after allogeneic bone marrow transplantation model (Stals et al., 1993a; Stals et al., 1993b) . Brown Norway rats were immunosuppressed with total body irradiation, inoculated with RCMV and transplanted with allogeneic bone marrow cells from Lewis rats. Animals were treated with either cidofovir (20 mg kg-1 of body weight as a single dose) or ganciclovir (20 mg kg-1 as two daily doses for 5 days). The effect of antiviral therapy was monitored by measuring RCMV titres in different organs and the histopathologic changes in lungs at 8-10 days post-infection. Treatment with ganciclovir resulted in a decrease in virus titres (lOglO PFU gram-1 of tissue) in lungs and spleens from 3.81 ± 0.34 and 4.2 ± 1.07 (untreated animals) to 1.26 ± 0.53 and 3.22 ± 0.27 (treated animals), respectively, whereas treatment with cidofovir resulted in a complete reduction of virus titres in all organs to below the detection level (P <0.01). In RCMV-infected allogeneic transplant recipients, severe diffuse thickening of alveolar septa (6.02 11M) with a diffuse infiltration of mononuclear cells occurred, whereas in the non-infected allogeneic transplant recipients, the septal width was 1.85 11M (P < 0.01). Antiviral treatment resulted in a reduction of the alveolar septal width to 4.67 ± 1.70 and 3.32 ± 0.63 11M after ganciclovir and cidofovir treatment, respectively. In addition, the influx of mononuclear cells in the alveolar septa was significantly reduced after treatment with cidofovir.
HSV and VZV models
Cidofovir has been evaluated for efficacy in an animal model of HSV-induced retinitis (Flores-Aguilar et al., 1994) . Culture medium containing HSV-1 was inoculated onto the retinal surface of rabbits. Retinitis developed rapidly (by day 3) and progressed to involve 50-70% of the retina by the end of week one. A single intravitreal dose of cidofovir (100 I1g) delayed retinitis when given up to 30 days prior to infection, whereas ganciclovir (200 I1g) was effective at 3, but not 7, days prior to infection.
Cidovir, potent anti-herpes activity 121 Bronson et al. (1990) showed that mice infected with HSV-2 had a significant difference in survival compared to placebo, with cidofovir at a total dose of 50 or 5 but not 0.5 mg kg-1 , regardless of whether cidofovir was given as one, two, three, five or 10 doses. These data support the efficacy of cidofovir with infrequent dosing. Yang and Datema (1991) extended these findings in the mouse HSV-2 model to encompass treatment regimens starting between 3 hand 5 days post-infection. Cidofovir and ganciclovir were tested in comparison. Cidofovir and ganciclovir appeared similarly effective when given as daily doses for 5 days. However, single dose (day 1) or two dose (days 1 and 3) therapy with cidofovir was more efficacious than the same dose of ganciclovir, especially for therapy initiated at days 4 or 5 post-infection. Soike et al. (1991) studied infrequent dosing regimens in the simian varicella virus model, a surrogate for VZV. Control animals (treated with saline) developed rash and viraemia, and died. A 50 mg kg-1 total dose of cidofovir was effective when treatments were initiated on day 2 post-infection, regardless of whether the dose was given as 10 daily doses of 5 mg kg-1 , five doses of 10 mg kg-1 on an every other day schedule, two doses of 25 mg kg-1 on days 2 and 7, or 50 mg kg-1 as a single dose on day 2 or day 4.
Prophylaxis with cidofovir has been evaluated in mice given a single dose of drug followed by intraperitoneal infection with HSV-2 (Yang and Datema, 1991) . Virus inoculation at 3 days after treatment with 3 or 10 mg kg-1 cidofovir resulted in less than 50% mortality, compared to 100% mortality in untreated animals. At a dose of 30 mg kg-1 , all animals survived, even when drug was administered as a single dose up to 4 days prior to virus inoculation.
Models with drug resistant virus
MCMV resistant mutants have been generated by in-vitro exposure of the wild type MCMV to increasing concentrations of cidofovir, ganciclovir or foscarnet (Smee et al., 1995) . The ganciclovir-resistant MCMV had a 9.5-fold increase in EC 5 0 for ganciclovir and was cross-resistant to foscarnet and cidofovir. The foscarnet-resistant MCMV had a 7-fold increase in EC 5 0 for foscarnet but remained sensitive to ganciclovir and cidofovir. The cidofovir-resistant MCMV had a 23.5-fold increase in EC 50 for cidofovir but remained sensitive to ganciclovir and foscarnet.
The cidofovir-resistant MCMV strain was much less pathogenic than the wild-type virus, as judged by its markedly attenuated ability to kill severe combined immunodeficient mice (Smee et al., 1995) . With equivalent virus inoculum, only one of 15 mice died with the mutant, compared to all 15 mice inoculated with the wild-type virus. Virus recovered from the mice, at or near death, maintained the drug-resistant phenotype.
By contrast, a similar inoculum of ganciclovir and foscarnet-resistant mutants caused a high mortality similar to the wild-type control strain. A similar experience was seen with a mutant HSV-2 selected in vitro as four-fold resistant to cidofovir. This HSV-2 mutant required 700-fold higher titre of virus than the wild-type to cause lethality in mice (Mendel et el., 1995b) . These data demonstrate that drug resistant mutants mayor may not have altered pathogenicity and illustrate the difficulty in attempting to extrapolate from in vitro susceptibility to clinical relevance.
Non-clinical metabolism and pharmacokinetic studies
Metabolism of cidofovir is a minor pathway of clearance and the majority (>80%) of an intravenous dose in all species studied is recovered unchanged in urine in 24 h.
The ability to measure low concentrations of drug by using radiolabel in monkeys has allowed the analysis of the plasma pharmacokinetics with a three compartment model (Cundy et el., 1996) . The alpha, beta and gamma half-lives were measured as 0.7, 3 and 35 h, respectively. The gamma phase, which represents less than 5% of the dose, is believed to represent phosphorylated drug in cells, and the half-life is consistent with measurements of the intracellular half-life of the active species, cidofovir diphosphate, in cell lines in tissue culture. An additional study in which urine was collected over a 7 day period from monkeys administered 14C-labelled cidofovir supported the long half-life and the lack of significant metabolite formation « 3%).
Tissue distribution studies with labelled cidofovir have shown concentrations of drug in the kidney that are much higher than in other tissues (Cundy et el., 1994) .
Toxicology
The principal systemic toxicity seen in animals is nephrotoxicity , which is dose-, scheduleand species-dependent. The target cell is the proximal convoluted tubule cell, and severity of histopathologic changes range from slight karyomegaly of the cell to tubular necrosis, loss of brush border and sloughing of the tubular epithelium. Mild-to-moderate lesions show decreased severity after a 4 week post-dose recovery period in chronic toxicology studies, suggesting reversibility. In addition, probenecid, dosed 1 h prior to cidofovir in long-term repeat dose monkey studies, reduced the severity of the nephrotoxicity.
Schedule dependency of the nephrotoxicity has been shown in several species. For example, a single dose of 50 mg kg-1 to monkeys results in no renal pathology, whereas 5 mg kg-1 day-1 for 10 days shows significant nephrotoxicity.
Nephrotoxicity is believed to result from accumulation of drug in the proximal convoluted tubule cells during the secretion process. The mechanism for this possibly involves faster uptake from the bloodstream at the basolateral membrane than the rate of eflux at the brush border. The evidence for this includes the relationship between species dependent sensitivity to nephrotoxicity and the reduction in kidney concentration seen with probenecid coadministration.
Clinical evaluation
Three Phase 1/11 and two Phase II/III studies using systemic administration in HCMV-infected patients with AIDS are detailed below. In addition, anecdotal clinical effects against acyclovir-resistant HSV have been reported with i.v, administration (Lalezari et sl., 1994) and with topical administration . Finally, anti-papilloma activity has recently been described for both direct intralesional injection (Van Cutsem et a/., 1994) as well as topical application (Snoeck et a/., 1995b) .
Phase 1/II Studies
Safety
The initial 30 patients enrolled in multiple dose Phase 1/11 studies received cidofovir at doses of 0.5-10 mg kg-1 given twice to once weekly. Doses up to 1.5 mg kg-1 given twice weekly were well tolerated and no increases in serum creatinine were observed (Polis et sl., 1995; Lalezari et el., 1995) . However, some patients receiving cidofovir at weekly or twice weekly doses of 3-10 mg kg-1 developed evidence of nephrotoxicity, manifested initially by proteinuria and glycosuria. In addition, 1 patient receiving 3 mg kg-1 and three patients receiving 10 mg kg-1 developed a serum creatinine~2 mg dl-1 .
The subsequent 34 patients received cidofovir at doses of 3-7.5 mg kg-1 given once weekly to once every 3 weeks. In addition, in attempt to ameliorate nephrotoxicity, these patients received concomitant probenecid and hydration with each dose of cidofovir. With these treatment modifications, 2 + proteinuria was observed in only 8 patients and none of the patients developed a serum creatinine of> 2 mg cr'.
Pharmacokinetics
One Phase 1/11 study (Wachsman et et., 1996) was primarily a pharmacokinetic and bioavailability study to assess the potential utility of oral and subcutaneous routes of cidofovir administration. Oral bioavailability was poor « 5%). Subcutaneous bioavailability was good (106 ± 16%); however, local intolerance (transient local ftbrosis) and the large volumes of formulation needed to administer therapeutic doses precluded further investigation. Combined pharmacokinetic data for i.v, administration from the three Phase 1/11 studies showed that levels of cidofovir were dose proportional over the range of 1.0-10 mg kg-1, and declined bi-exponentially with a terminal half-life of 2.6 ± 1.2 h. Approximately 90% of the dose was recovered unchanged in the urine in 24 h. Total serum clearance approximated renal clearance, but was significantly higher than creatinine clearance, suggesting a contribution from tubular secretion. Oral probenecid appeared to block tubular secretion and to reduce clearance to the level of glomerular filtration. At the doses proposed for clinical use (3 and 5 mg kg-\ the maximum plasma concentrations of cidofovir are 7.3-20 Ilg mr' (about 26-72 11M) . Thus, concentrations that are associated with an anti-HCMV effect in vitro (mean 10 5 0 =0.6-0.7 11M for wild-type and foscarnet resistant strains) are achieved and maintained for an extended time period (~6 h). Plasma concentrations above the average 10 5 0 for ganciclovir-resistant strains (mean 10 50 = 7.5 11M) are maintained for a minimum of 4 h, potentially allowing for efficacy with cidofovir after ganciclovir treatment failure.
While consideration of plasma drug concentrations is of interest, the intracellular concentrations of cidofovir and its active metabolites are the more important parameters for antiviral activity. Although pharmacokinetic data on intracellular concentrations have not been obtained in humans, the prolonged y-phase half-life in plasma and urine measured in monkeys (t1/2~36 h by 14C-labelled drug) is believed to reflect intracellular clearance. These data provide a rationale for persistent antiviral effects even when cidofovir blood levels fall below the concentrations needed to elicit antiviral effects in vitro under continuous exposure conditions.
Antiviral activity
8tudy G8-92-101 evaluated four i.v, dose levels (0.5, 1.0. 3.0 and 10 mg kg-1) of cidofovir Cidovir, potent anti-herpes activity 123 alone, and three dose levels (3.0, 5.0 and 7.5 mg kg-1) of cidofovir with concomitant oral probenecid. Initially four doses, each a week apart, were studied, although patients were able to elect maintenance beyond 4 weeks. Additionally, interval extensions to 2 or 3 weeks were also' studied (Table 5 ). In the semen of patients receiving 0.5 or 1.0 mg kg-1 there was no antiviral response (:2:1 DO-fold reduction in HCMV plaque forming units), whereas 3 of 5 and 4 of 4 at 3.0 and 10 mg kg-1, respectively, had responses. Patients receiving concomitant probenecid with 3.0, 5.0 or 7.5 mg kg-1 cidofovir, also showed an antiviral response (in 3 of 5, 3 of 4 and 1 of 1 patients, respectively), suggesting that the antiviral effectiveness of cidofovir was not reduced in presence of concomitant probenecid. As with semen, effects on urine culture were minimal at 0.5 and 1.0 mg kg-1, but pronounced at :2:3 mg kg-1. The antiviral effect in urine was also maintained with probenecid present in the dosing regimen. Comparison of pooled data for dose groups of :2:3 mg kg-1 vs. < 3 mg kg-1 showed a statistically significant difference for antiviral response in both semen and urine (P < 0.005 for each, see Lalezari et al., 1995) .
8tudy G8-92-103 evaluated three i.v, doses (0.5, 1.0 and 5 mg kg-1) of cidofovir alone and two doses (5 and 7.5 mg kg-1) of cidofovir with concomitant oral probenecid. At cidofovir doses of 1.5 mg kg-1 twice weekly or less, two of the eight patients had conversion of urine cultures to negative: Of the four patients receiving cidofovir at 5 mg kg-1 twice weekly, three had negative urine cultures by the third week of study medication. Of note, one of these patients had a persistent negative urine culture until week 8, 5 weeks after the last cidofovir infusion. Of eight patients receiving cidofovir at 5 mg kg-1 weekly and 7.5 mg kg-1 every 3 weeks, four had negative urine cultures after one dose of cidofovir, and all eight had negative urine cultures on at least one occasion. Two patients had negative cultures up to 2 months after the last dose of cidofovir. The data from sequential urine cultures demonstrated a prolonged in-vivo anti-HCMV effect of cidofovir. Conversion of qualitative blood cultures from positive 
Data from Lalezari et al., 1995. 'A response in semen is a value for number of plaque forming units that is~1 DO-foldlower than the baseline value.
to negative was not seen; however, a quantitative reduction would not have been measured by the assay employed. Additionally, culture specimens were taken pre-dose, l.e, 1 to 3 weeks subsequent to the preceding dose, at a time when blood levels of cidofovir would be negligible. Compilation of data from studies GS-92-101 and GS-92-103 showed that in patients receiving cidofovir at doses 2':3 mg kg-1 , the virologic response rate was 93% for urine and 74% for semen. These data from the Phase 1/11 trials were an important component in the selection of doses for the Phase II/III studies. In addition, the long duration of the antiviral responses seen in semen and urine allowed the selection of an infrequent administration schedule.
An additional component of the GS-92-101 study was the attempt to assess the development of drug resistance by determination of cidofovir susceptibility of HCMV isolates obtained prior to or subsequent to cidofovir exposure (Cherrington et el., 1996) . Isolates from 22 patients were assessed. Fifteen had cidofovir exposure at a single dose level and seven had two cidofovir exposure periods, each at different doses; the second exposure period began between 1 and 32 weeks after the end of the first exposure period. Thus, 29 pairs of initial (pre-exposure) and follow-up (post-exposure) isolates were assayed. Initial isolates were obtained immediately before cidofovir was administered at a specific dose and follow-up isolates were obtained at a median of 8 (range, 3-36) weeks later. The patients were administered a median cumulative dose of 30 (range, 3-67) mg kg-1 over a median period of 8 (range, 2-38) weeks. Nine patients (6 at 3 mg kg-1 and 3 at 5 mg kg-1 ) received cidofovir for more than 12 weeks, and three patients received cidofovir intermittently (in 2 exposure periods) for > 1 year. The overall ranges of IC so values were < 0.5-1.85 and < 0.5-2.0 flM for 29 initial and 29 follow-up isolates, respectively, demonstrating no shift in. susceptibility after drug exposure. The change from baseline also showed no particular trend; 21 follow-up isolates were considered unchanged « 2-fold) whereas four were increased (2-to 4fold) and four were decreased (2-to 4-fold) to a small extent. Thus, no significant changes in susceptibilities to cidofovir were found for HCMV isolates from patients exposed to various regimens of cidofovir in this clinical trial.
Phase II/III Studies
Three Phase II/III studies were initiated to assess the safety and efficacy of intravenous cidofovir for the treatment of HCMV retinitis. Data from two of these studies are described below. The third trial, which is ongoing, is being conducted by the Studies of the Ocular Complications of AIDS (SOCA) clinical trial network.
In September -1 October, 1995), 48 patients with previously untreated peripheral CMV retinitis were randomized to receive either immediate cidofovir therapy (n = 25) or deferred therapy (n = 23) (no treatment until HCMV retinitis progression was documented). Patients randomized to the deferred group were eligible to crossover and receive cidofovir therapy following documentation of HCMV retinitis progression. Intravenous cidofovir 5 mg kg-1 was administered once weekly for the first two weeks (induction), then once every other week (maintenance) until HCMV retinitis progression, treatment limiting toxicity, or death. Oral probenecid and intravenous saline hydration were given with each cidofovir infusion to minimize the potential for nephrotoxicity. The study endpoint was time to HCMV retinitis progression, as assessed by retinal photographs read by an ophthalmologist masked to randomization assignment. Median time to HCMV retinitis progression was 22 days for the deferred group and 120 days for the immediate cidofovir treatment group (P < 0.000006). Fifteen patients randomized to deferred therapy crossed-over to cidofovir therapy following HCMV retinitis progression. The median time to HCMV retinitis progression on deferred therapy for this subset of patients was 19 days and their median time to HCMV retinitis progression on crossover cidofovir therapy had not yet been reached (P = 0.0002). Proteinuria (23%) and neutropenia (15%), both without clinical sequelae, were the most frequent adverse experiences felt by the investigators to be possibly or probably related to study drug. Cidofovir was discontinued prior to HCMV retinitis progression in 5 of 40 (13%) patients for 2':2 + proteinuria and 2 of 40 (5%) patients for a serum creatinine of 2-3 mg dl-1 upon discontinuation of therapy; both the proteinuria and the serum creatinine elevations were partially reversible upon discontinuation of therapy. Probenecid reactions consisting of mild to moderate reversible constitutional symptoms and/or rash were observed in 22 of 40 (55%) patients, but were dose-limiting in only 2 (5%) patients. Survival was similar in the immediate and deferred groups, and was consistent with historical data for this patient population.
To place this result into some perspective it is worth considering the available data from previous clinical trials of deferred therapy against either intravenous ganciclovir (Spector et al., 1993) or foscarnet (Palestine et al., 1991) . These trials used the same study endpoint for efficacy in comparable study populations (Le. newly diagnosed peripheral HCMV retinitis in patients with AIDS). The median times to HCMV retinitis progression were 13.5 and 49.5 days for deferred therapy vs. ganciclovir, respectively, and 21 and 52.5 days for deferred therapy vs. foscarnet (Polis, 1992) , respectively.
The second study (Lalezari, J. P. et al. Abstract, 35th International Conference on Antimicrobial Agents & Chemotherapy, San Francisco, 17-20 September, 1995) enrolled patients who previously had progression of their CMV retinitis despite receiving both ganciclovir and foscarnet (alone or in combination) or one of these agents and intolerance to the other. Patients were randomized to receive intravenous cidofovir at 5 mg kg-1 once weekly for 2 weeks (induction), then 5 mg kg-1 once every other week (Group A) or 3 mg kg-1 once every other week (Group B) until HCMV retinitis progression, treatment-limiting toxicity, or death. Concomitant oral probenecid and intravenous normal saline were given with each cidofovir infusion to minimize the potential for nephrotoxicity. The study endpoints were time to HCMV retinitis progression, as assessed by retinal photographs read at a central reading centre by an ophthalmologist unaware of group assignment, and safety. An interim intent-to-treat analysis was conducted on data from the first 60 patients (n = 29 for Group A and n = 31 for Group B). The baseline patient characteristics were comparable between Groups A and B (e.g. median CD4 =7 and 5 cells rnrn"), Patients had received a median of 4 courses of systemic ganciclovir and/or foscarnet and 12 patients had received local anti-HCMV therapy. The median times to HCMV retinitis progression were 115 days (Group A) and 49 days (Group B). These were not significantly different statistically (P = 0.12) possibly due to the limited number of patients (60) in the interim analysis. Additional patient enrollment is ongoing and subsequent data analysis will help to assess if this difference is real. Regardless of the outcome, these results compare quite favourably with historical data from the SOCA study (Studies of Ocular Complications of AIDS Research Group et al., 1994) that show median progression times for foscarnet and ganciclovir of 53 and 47 days for first, 35 and 42 days for second and 33 and 35 days for third progressions, respectively. The safety data supported a manageable side-effect profile. Two of 29 (7%) patients in Group A and 2 of 31 (7%) patients in Group B developed a serum creatinine of~2 mg cr'. Mild to moderate probenecid reactions consisting of reversible constitutional symptoms and/or rash were observed in 29 of 60 (48%) patients; 2 (3%) patients had serious, but reversible reactions. Survival was similar in the two groups and consistent with historical controls.
The data from these two Phase II/III trials demonstrate that cidofovir is efficacious in delaying the progression of both previously untreated and relapsing HCMV retinitis in patients with AIDS. The nephrotoxic potential can be managed using the combined approach of pre-dose monitoring of renal function and concomitant adrninistration of hydration and probenecid. Finally, the administration schedule for cidofovir is very convenient compared to the schedule of existing i.v, therapies for HCMV disease that require administrations daily (or multiple times daily).
